Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Trading Statement

30 Nov 2005 07:04

Original Investments PLC30 November 2005 Original Investments PLC ("Original Investments" or "the Company") Acrobot update An innovative medical device, enabling orthopaedic surgeons to accurately planand perform hip resurfacing surgery, has been granted a CE-mark by BSI'sCertification Panel. The surgical navigation product has been developed by TheAcrobot Company ("Acrobot") in which Original Investments, the AIM-quotedinvestment company, has a 25% shareholding. The device has been developed incollaboration with Corin Group PLC ("Corin"), and the CE-mark is themanufacturer's guarantee that the device meets all the required Europeanmanufacturing and safety standards. Acrobot develops surgical systems for minimally-invasive, bone-conservingorthopaedic surgery. The new device, called Acrobot(R) Navigation, is beingcommercialised by Corin, under the name of Wayfinder(R), to enable accurateimplantation of the company's metal on metal hip resurfacing implant.Clinical trials are to start immediately at a London hospital. Justin Cobb,Professor of Orthopaedics at Imperial College, will lead the alpha site. Twoadditional sites in the UK and a third in Australia will start evaluation of theAcrobot(R) Navigation system in the second quarter of 2006. The device will bein wider use from the second half of 2006. The Acrobot(R) Navigation system gives the surgeon the ability to accuratelyimplant hip resurfacing prostheses in a minimally invasive procedure. It differsfrom competitive products by using mechanical tracking rather than optical orelectromagnetic technologies, giving it a higher accuracy at a lower cost.Acrobot believes that this unique selling point will increase the use of thetechnology, making it accessible to a larger number of surgeons and patients.The Acrobot(R) Navigation system has been developed by the Acrobot team at thecompany's laboratories in London. Acrobot is seeking licensees and distributorsfor applications of Navigation to other orthopaedic procedures. It is the secondof a number of related products to be produced by Acrobot, having launched theAcrobot(R) Planner software and service last month. A third product planned forlaunch in 2006 is the Acrobot(R) Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. Enquiries to: Dr. Paula Gomes, Director of OperationsThe Acrobot Company Ltd, Tel: +44 (0)20 7403 5866, Email:enquiries@acrobot.co.ukor Terry Bond, Managing Director, Original Investments PLC 44 (0) 1235 834734.Email: tb@originalinvestments.com About The Acrobot Company Ltd The Acrobot Company Ltd develops precision surgical systems for minimallyinvasive, bone conserving, orthopaedic surgery. The Company was founded sixyears ago by Imperial Innovations as a collaboration to combine the skills ofclinicians and academics Using proprietary surgical planning software andstate-of-the-art Hands-On Robotics(TM), and Passive Constraint Navigation(TM)systems, Acrobot's products assist surgeons in achieving better patient outcomesby improving surgical precision and reducing surgical errors, while loweringoverall procedure cost. About Original Investments PLC Original Investments PLC, formerly called BioProjects International PLC, isquoted on the AIM market of the London Stock Exchange. The Company specializesin providing finance for early-stage companies that can demonstrate immediategrowth prospects and significant financial potential. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.